RELMADA THERAPEUTICS, INC.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- RLMDRelmada Therapeutics, Inc.0Calm
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Signing up patientsPhase 270 patientsMain results: Nov 2027 - RLMDRelmada Therapeutics, Inc.0Calm
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer
Not started yetPhase 3393 patientsMain results: Dec 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 4 purchases
- Shenouda MagedChief Financial Officer · Sep 10, 2026Bought 79,800 sharesabout $339 thousand ·
- TRAVERSA SERGIOChief Executive Officer · Sep 10, 2026Bought 100,000 sharesabout $410 thousand ·
- Shenouda MagedChief Financial Officer · Sep 9, 2026Bought 120,200 sharesabout $505 thousand ·
- TRAVERSA SERGIOChief Executive Officer · Sep 9, 2026Bought 100,000 sharesabout $418 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.